AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12182952
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion of fat
Trial: 10359029
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF), 1000 mg/m2/d
Trial: 10359029
Drug: Azathioprine (AZA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (AZA), 2 mg/kg on the first post-operative day
Trial: 8557012
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of rocuronium (9.9 +/- 1.3 micrograms kg-1 min-1)
Trial: 8557012
Drug: Surgical patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical patients receiving comparable infusions
Trial: 29738405
Drug: Group aerobic
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group aerobic and strength training (twice weekly for 24 weeks, 60 minutes each session using ankle weights, latex resistance bands, and dumbbells)
Trial: 26813471
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of valsartan (group B)
Trial: 26813471
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of valsartan combined with tacrolimus (group C)
Trial: 26813471
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of valsartan (group A)
Trial: 20352259
Drug: Laparoscopic cholecystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic cholecystectomy + irrigation of gallbladder bed with 20 mL 0.5% bupivacaine solution
Trial: 20352259
Drug: Laparoscopic cholecystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic cholecystectomy + irrigation of gallbladder bed with bupivacaine + 10 mL 0.5% bupivacaine solution every 6 h
Trial: 17606880
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide 500 mg once daily for 4 days combined with oral prednisone 60 mg once daily for 5 days (n = 16)
Trial: 17606880
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide and prednisone (treatment group)
Trial: 10458232
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with ifosfamide/etoposide on days 1-3 and cyclophosphamide/doxorubicin on day 5, followed by granulocyte colony-stimulating factor; maintenance included four alternating cycles of ifosfamide/etoposide and doxorubicin/CTX.
Trial: 10458232
Drug: CTX dose
RxNorm normalized name: CTx-PDE6b
DrugBank: CTx-PDE6b (DB17858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX dose levels during maintenance (two arms).
Trial: 10458232
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen including dose-intensification.
Trial: 7563558
Drug: 22-mg transdermal
RxNorm normalized name: methylphenidate 2.22 MG/HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-mg transdermal nicotine therapy with minimal counseling
Trial: 7563558
Drug: 44-mg transdermal
RxNorm normalized name: moxidectin 1.44 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44-mg transdermal nicotine therapy with minimal counseling
Trial: 7563558
Drug: 22-mg transdermal
RxNorm normalized name: methylphenidate 2.22 MG/HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-mg transdermal nicotine therapy with individual counseling
Trial: 7563558
Drug: 44-mg transdermal
RxNorm normalized name: moxidectin 1.44 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44-mg transdermal nicotine therapy with individual counseling
Trial: 7563558
Drug: 22-mg transdermal
RxNorm normalized name: methylphenidate 2.22 MG/HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-mg transdermal nicotine therapy with group counseling
Trial: 7563558
Drug: 44-mg transdermal
RxNorm normalized name: moxidectin 1.44 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44-mg transdermal nicotine therapy with group counseling
Trial: 7563558
Drug: Minimal contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal contact treatment
Trial: 7563558
Drug: 44-mg transdermal
RxNorm normalized name: moxidectin 1.44 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44-mg transdermal nicotine therapy
Trial: 7563558
Drug: 22-mg transdermal
RxNorm normalized name: methylphenidate 2.22 MG/HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-mg transdermal nicotine therapy
Trial: 115801
Drug: Intranasal self‐administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal self‐administration of an aqueous solution of a glutaraldehyde‐treated timothy grass pollen allergen
Trial: 30540715
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (IV TXA) 2g (1g before incision and 1g before wound closure)
Trial: 30540715
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (PO TXA) 1.95g 2 hours preoperatively
Trial: 27236888
Drug: Xinfeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng Capsule (XFC), 0.5 g each pill, three pills each time, 3 times per day for 3 months
Trial: 27236888
Drug: Sulfasalazine (SASP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SASP), 0.25 g per tablet, 4 tablets each time, twice per day for 3 months
Trial: 25256187
Drug: BDD-NET (therapist-supported,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDD-NET (therapist-supported, Internet-based cognitive-behavioral therapy) for 12 weeks
Trial: 22493419
Drug: Trastuzumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (4 mg loading dose followed by 2 mg weekly)
Trial: 22493419
Drug: Lapatinib (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,500 mg orally daily)
Trial: 22493419
Drug: Trastuzumab and
RxNorm normalized name: pertuzumab and trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab and lapatinib (1,000 mg orally daily)
Trial: 22493419
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (control group not explicitly defined)
Trial: 20138357
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery (APCam01)
Trial: 20138357
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery (APCam03)
Trial: 17179256
Drug: Landiolol at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol at 0.1 mg/kg infused 4 min before intubation in normotensive patients
Trial: 17179256
Drug: Landiolol at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol at 0.2 mg/kg in hypertensive patients
Trial: 17179256
Drug: Fentanyl at
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl at 2 μg/kg
Trial: 17179256
Drug: Landiolol (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (any dose)
Trial: 12488239
Drug: buspirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone (10 mg twice daily)
Trial: 12488239
Drug: paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paroxetine (20 mg daily)
Trial: 12488239
Drug: venlafaxine-XR (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine-XR (75 mg daily)
Trial: 9121851
Drug: 2-hourly CPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hourly CPT
Trial: 9121851
Drug: 4-hourly CPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hourly CPT
Trial: 1292072
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg capsule three times daily
Trial: 1292072
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (multiple-vitamin tablet three times daily)
Trial: 3966421
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg PN X HCl
Trial: 3966421
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg PN X HCl
Trial: 3966421
Drug: 10.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mg PN X HCl
Trial: 3966421
Drug: 20.0 mg
RxNorm normalized name: RUXOLITINIB 20.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.0 mg PN X HCl
Trial: 27926661
Drug: Low-dose prostacyclin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prostacyclin infusion (1.0 ng/kg/min)
Trial: 24373022
Drug: Paramedian inserted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paramedian inserted mini-implants
Trial: 24373022
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (median mini-implants of the same size)
Trial: 15076779
Drug: Anesthesia (lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia (lidocaine injected into the anterior talofibular and calcaneofibular ligament, 1.5 cc each)
Trial: 11818693
Drug: Interferon-alpha alone
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha alone or in combination with ribavirin
Trial: 9803049
Drug: Prolonged transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged transdermal fentanyl (FENtd)
Trial: 8087191
Drug: Aluminium-adsorbed pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium-adsorbed pertussis vaccine
Trial: 8087191
Drug: Non-adsorbed pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adsorbed pertussis vaccine
Trial: 8087191
Drug: Two-component vaccine
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-component vaccine as primary immunization
Trial: 8087191
Drug: Monocomponent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monocomponent vaccine as primary immunization
Trial: 27765695
Drug: 1,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 IU daily
Trial: 27765695
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU weekly
Trial: 17543413
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pioglitazone once daily for 6 months
Trial: 15146932
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide 5‐mononitrate (5‐ISMN) tablet
Trial: 15146932
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide 5‐mononitrate intravenous infusion
Trial: 15146932
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide dinitrate (ISDN) intravenous infusion
Trial: 11219479
Drug: Fluvastatin ER
RxNorm normalized name: fluvastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin ER 80 mg QPM
Trial: 11219479
Drug: Fluvastatin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin IR 40 mg QPM
Trial: 11219479
Drug: Fluvastatin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin IR 40 mg BID
Trial: 2739019
Drug: Antilipid A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilipid A antibody
Trial: 474664
Drug: Animal supplements
RxNorm normalized name: animals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal supplements
Trial: 474664
Drug: Vegetable supplements
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable supplements
Trial: 28723837
Drug: Lidocaine 1.5%
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5% with epinephrine 5 μg/mL
Trial: 15059069
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B lipid complex (ABLC) at 1 mg/kg/d
Trial: 15059069
Drug: Conventional amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional amphotericin B (c‐AmB) at 0.6 mg/kg/d
Trial: 2421751
Drug: xamoterol 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol 0.025 mg kg‐1
Trial: 31211469
Drug: Typing pattern
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typing pattern monitored remotely during a 6-month follow-up while dopaminergic medications were being titrated.
Trial: 31211469
Drug: Novel algorithm
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel algorithm based on recursive neural networks for detecting responses to medication.
Trial: 31211469
Drug: Dopaminergic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic treatment titration.
Trial: 30084893
Drug: Telephone-administered interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered interpersonal psychotherapy (tele-IPT)
Trial: 24625273
Drug: Ultrasound-guided subacromial
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided subacromial corticosteroid injection and a physiotherapist-led exercise programme
Trial: 24625273
Drug: Ultrasound-guided subacromial
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided subacromial corticosteroid injection and an advice and exercise leaflet
Trial: 24625273
Drug: Blind subacromial
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind subacromial corticosteroid injection and a physiotherapist-led exercise programme
Trial: 24625273
Drug: Blind subacromial
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind subacromial corticosteroid injection and an advice and exercise leaflet
Trial: 24625273
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between injection interventions
Trial: 15741836
Drug: Pizotifen (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen (1.5 mg)
Trial: 10213009
Drug: irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan (CPT-11) at a dose of 350 mg/m2 every 3 weeks
Trial: 7537967
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight (LMW) heparin
Trial: 2170885
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of radiation therapy
Trial: 25785441
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg) + Zinc (30 mg/d) + Selenium (150 μg/d)
Trial: 24015990
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (200 mg iron sucrose, three daily infusions starting within 24 hours of admission)
Trial: 21412833
Drug: LEV 500
RxNorm normalized name: Cetylev 500 MG Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 500 mg/day
Trial: 21412833
Drug: LEV 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 1,000 mg/day
Trial: 14749240
Drug: Flaxseed (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (25 g ground flaxseed muffin)
Trial: 14749240
Drug: Soy (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy (25 g soy flour muffin)
Trial: 11545629
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin (0.3% ophthalmic solution every 30 minutes for 4 hours before surgery)
Trial: 11545629
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (0.3% ophthalmic solution every 30 minutes for 4 hours before surgery)
Trial: 11545629
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical and oral ofloxacin (one 400-mg tablet administered 24-26, 12-14, and 2 hours before surgery)
Trial: 11545629
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical and oral ciprofloxacin (four 100-mg tablets administered 24-26, 12-14, and 2 hours before surgery)
Trial: 11545629
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical and oral therapy with ofloxacin
Trial: 11545629
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy alone (ofloxacin)
Trial: 3122381
Drug: Mannitol 20%
RxNorm normalized name: mannitol 20% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 20% (250 ml) with moderate hydration (2.5 L)
Trial: 23277304
Drug: Social learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social learning and cognitive behavioral therapy
Trial: 21450262
Drug: Imagining daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagining daily activities (DA) for 5 minutes per day over two weeks
Trial: 18974717
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg.kg(‐1) body mass
Trial: 16816222
Drug: Oxcarbazepine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (mean dose=1515 mg/day)
Trial: 12960189
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of glucose metabolism with duration of deafness in postlingually deaf patients
Trial: 10596684
Drug: Bradykinin inhalation
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin inhalation
Trial: 10596684
Drug: Inhaled L‐ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled L‐ASA (90 mg/mL, 4 mL)
Trial: 8537687
Drug: Pneumococcal glycoprotein
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal glycoprotein conjugate vaccine (serotypes 6B, 14, 18C, 19F, and 23F linked to CRM197)
Trial: 31725692
Drug: Preoperative acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative acetaminophen and carbohydrate drinks
Trial: 22167079
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with Improvac (2 ml s. c.); administered at 12 weeks and 18 weeks
Trial: 20020791
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic + intravenous ketorolac tromethamine
Trial: 20020791
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac tromethamine alone
Trial: 15068574
Drug: Tailored, nurse-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored, nurse-administered smoking cessation intervention with telephone counseling
Trial: 7768259
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan (16 mg)
Trial: 7768259
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan (up to 400 mg)
Trial: 373358
Drug: Fenfluramine therapy
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine therapy
Trial: 6404954
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg three times a day
Trial: 29843899
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) 24 Gy
Trial: 22476616
Drug: Glucosidase inhibitors
RxNorm normalized name: Alpha glucosidase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosidase inhibitors
Trial: 18243498
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months goserelin followed by no additional therapy